Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Novartis Pharmaceuticals UK Ltd
Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
Telephone: +44 (0)1276 692 255
Fax: +44 (0)1276 698 449
Medical Information Direct Line: +44 (0)1276 698 370
Medical Information e-mail: medinfo.uk@novartis.com
Customer Care direct line: +44 (0)845 741 9442

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Patient Information Leaflet last updated on the eMC: 03/05/2012
PIL Rasilez tablets 150 mg

Following a review of the results of the ALTITUDE clinical study, the prescribing information for Rasilez is being updated to include new contraindications and warnings for the use of Rasilez in combination with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs).

The updated Summary of Product Characteristics will be available on the eMC as soon as it has been approved.

Further information is available from the MHRA website.


The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. This PIL is in PDF format.

View Patient Information Leaflet (0.136MB)

Are you having problems reading or printing this PDF? Visit adobe.com and download the Adobe Acrobat Reader.


More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/20050/PIL/


Black Triangle

This medicine is monitored intensively by the CHM and MHRA

Active Ingredients/Generics

 
  aliskiren hemifumarate